<DOC>
	<DOCNO>NCT01327911</DOCNO>
	<brief_summary>This study phase 1 , open label , non-randomized , multi-center , pilot study evaluate safety tolerability NT-501 implant 5-7 study participant Mactel .</brief_summary>
	<brief_title>Ciliary Neurotrophic Factor ( CNTF ) Safety Trial Patients With Macular Telangiectasia ( Mactel )</brief_title>
	<detailed_description>Protocol Extended Follow-up Phase 1 Multicenter Open Label Safety Tolerability Clinical Trial Ciliary Neurotrophic Factor ( CNTF ) Patients Macular Telangiectasia Type 2 ( MacTel )</detailed_description>
	<mesh_term>Telangiectasis</mesh_term>
	<criteria>The participant must offer sufficient opportunity review inform consent form , agree form 's content sign protocol 's informed consent ; The participant must bilateral MacTel ; Women childbearing potential men must agree use effective form birth control study ; Participant must medically able undergo ophthalmic surgery ECT implant ; The participant 's bestcorrected visual acuity 64 letter well ( 20/50 well ) study eye ; Participant &lt; 21 year age ; Participant medically unable comply study procedure follow visit ; Participant evidence ocular disease MacTel may confound outcome study ( e.g. , diabetic retinopathy manifest macular edema , uveitis , etc . ) ; Participant chronic requirement ( e.g. , â‰¥ 4 week time ) ocular medication and/or diagnosed disease , judgment examine physician , may vision threaten may affect primary outcome ( artificial tear permit ) ; Participant evidence subretinal neovascularization either eye ; Participant evidence central serous chorioretinopathy ( CSR ) either eye ; Participant evidence pathologic myopia either eye ; Participant vitrectomy , penetrate keratoplasty , trabeculectomy trabeculoplasty ;</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Mactel</keyword>
	<keyword>Macular Telangiectasia Type 2</keyword>
</DOC>